Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for
one third of the total approved mAbs, are formulated with high protein concentration (100 …

The protein folding problem was first articulated as question of how order arose from
disorder in proteins: How did the various native structures of proteins arise from interatomic …

Tangential flow filtration is an efficient membrane separation technology utilized across a
wide range of industries for separation and purification applications. The requirement of …

Machine learning has been recently used to predict therapeutic antibody aggregation rates
and viscosity at high concentrations (150 mg/ml). These works focused on commercially …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Looking at globular proteins with the eyes of a colloid scientist has a long tradition, in fact a
significant part of the early colloid literature was focused on protein solutions. However, it …

Attractive protein–protein interactions in concentrated monoclonal antibody (mAb) solutions
may lead to the formation of clusters that increase viscosity. Here, we propose an analytical …

The effects of a subclass of monoclonal antibodies (mAbs) on protein–protein interactions,
formation of reversible oligomers (clusters), and viscosity (η) are not well understood at high …

Excipients are substances that are added to therapeutic products to improve stability,
bioavailability, and manufacturability. Undesirable protein–protein interactions (PPI) can …

CENTAUR has been selected as one of the eight initial instruments to be built at the Second
Target Station (STS) of the Spallation Neutron Source at Oak Ridge National Laboratory. It is …